Creativ-Ceutical, 215 rue du Faubourg Saint Honoré, 75008 Paris, France.
Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):71-94. doi: 10.1586/erp.11.94.
A review of worldwide economic evaluations of pertussis booster vaccination for adolescents and adults was conducted. Thirteen cost-effectiveness, cost-utility and economic impact models were identified. The most frequently studied strategies were adolescent booster, one-time adult booster, adult decennial boosters and cocoon strategy. All studies evaluating adolescent booster suggested this was a cost-effective or cost-saving strategy compared with no booster vaccination. Conclusions concerning adult vaccination, alone or in combination with adolescent vaccination, vary between studies. Studies were often strongly affected by assumptions regarding the amount of unreported cases and lack of reliable input data on real incidence, other epidemiological inputs, costs associated with mild disease and herd immunity effects. Reviewed studies were generally in favor of pertussis booster vaccination, but did not identify any optimal vaccination strategy. Future economic evaluations should explore a wider range of strategies, taking into account country-specific considerations.
对全球范围内百日咳青少年和成人加强免疫接种的经济学评价进行了综述。确定了 13 种成本效益、成本效用和经济影响模型。研究最多的策略是青少年加强免疫、一次性成人加强免疫、成人十年加强免疫和窝边策略。所有评估青少年加强免疫的研究都表明,与不进行加强免疫接种相比,这是一种具有成本效益或节省成本的策略。关于成人接种疫苗的结论,无论是单独接种还是与青少年接种疫苗联合接种,在不同的研究中存在差异。研究结果往往受到未报告病例数量的假设以及缺乏可靠的真实发病率数据、其他流行病学输入、轻度疾病相关成本和群体免疫效应等因素的严重影响。综述研究普遍支持百日咳加强免疫接种,但未确定任何最佳接种策略。未来的经济评估应探索更广泛的策略,同时考虑到特定国家的具体情况。